Drug Type Trispecific T-cell engager (TriTE) |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3ε inhibitors(CD3e molecule inhibitors), CD8 inhibitors(Cluster of differentiation 8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Preclinical | CN | - | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Preclinical | CN | - |